| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 06/25/2002 | US6410007 Erectile dysfunction, vasodilation |
| 06/25/2002 | CA2220024C Thiazolidine-4-carboxylic acid derivatives as cytoprotective agents |
| 06/25/2002 | CA2215210C Polyphenol fractions of tea, the use thereof and formulations containing them |
| 06/25/2002 | CA2203878C Certain substituted benzylamine derivatives; a new class of neuropeptide y1 specific ligands |
| 06/25/2002 | CA2031384C Active component concentrates and new active component combinations from ginkgo biloba leaves, their method of preparation and pharmaceuticals containing the active component concentrates or the active component combinations |
| 06/23/2002 | WO2002040654A2 A human serpin secreted from lymphoid cells lsi-01 |
| 06/23/2002 | CA2429179A1 Polynucleotide encoding a novel human serpin secreted from lymphoid cells lsi-01 |
| 06/22/2002 | CA2365673A1 Methods, compositions and kits relating to cardiovascular disease |
| 06/20/2002 | WO2002048715A2 Inflammatory markers for detection and prevention of diabetes mellitus |
| 06/20/2002 | WO2002048358A2 Regulation of human chemokine-like receptor |
| 06/20/2002 | WO2002048337A2 Secreted human proteins |
| 06/20/2002 | WO2002048180A2 Peptides and/or proteins and use thereof for the production of a therapeutic and/or prophylactic medicament |
| 06/20/2002 | WO2002048179A1 Gamma-ketoacid dipeptide derivatives as inhibitors of caspase-3 |
| 06/20/2002 | WO2002048152A2 Spiro[isobenzofuran-1,4'-piperidin]-3-ones and 3h-spiroisobenzofuran-1,4'-piperidines |
| 06/20/2002 | WO2002048148A2 Pyrazolopyridine derivatives |
| 06/20/2002 | WO2002048145A1 Aminotriazolopyridiine derivatives as adenosine receptor ligands |
| 06/20/2002 | WO2002048134A2 Di-substituted aminomethyl chroman derivative beta-3 adrenoreceptor agonists |
| 06/20/2002 | WO2002048131A1 Arylated furane and thiophene carboxylic acid amides with potassium channel blocking effect |
| 06/20/2002 | WO2002048124A2 Piperazine derivatives |
| 06/20/2002 | WO2002048117A1 Quinazolinone derivatives |
| 06/20/2002 | WO2002048114A1 Phenylacetamido- pyrazole derivatives and their use as antitumor agents |
| 06/20/2002 | WO2002048099A1 Carboxylic acid amide derivatives and their use in the treatment of thromboembolic diseases and tumours |
| 06/20/2002 | WO2002048096A1 Hydrazone derivatives and use thereof in medicines |
| 06/20/2002 | WO2002047762A1 Serine protease inhibitors |
| 06/20/2002 | WO2002047723A1 Medicinal compositions having improved water-solubility |
| 06/20/2002 | WO2002047719A2 Survical promoting ncam binding and ncam ligand biding compounds |
| 06/20/2002 | WO2002047716A2 Chronic treatment regimen using glucagon-like insulinotropic peptides |
| 06/20/2002 | WO2002047714A1 Management of the consequences of fetal programming |
| 06/20/2002 | WO2002047712A2 Peptide yy and peptide yy agonists for treatment of metabolic disorders |
| 06/20/2002 | WO2002047711A2 Modulators of activity of g-protein-coupled receptor kinases |
| 06/20/2002 | WO2002047710A2 Use of inhibitors of lyn-associated signal transduction (last) in the treatment of prostate cancer |
| 06/20/2002 | WO2002047708A2 Selective cox-2 inhibition from edible plant extracts |
| 06/20/2002 | WO2002047706A2 Selective cox-2 inhibition from plant extracts |
| 06/20/2002 | WO2002047701A1 Composition comprising melissa leaf extract for anti-angiogenic and matrix metalloproteinase inhibitory activity |
| 06/20/2002 | WO2002047699A1 Compositions for preventing or ameliorating multiple risk factor syndromes |
| 06/20/2002 | WO2002047687A1 Urotensin-ii receptor antagonists |
| 06/20/2002 | WO2002047685A2 Nmda receptor agonist pharmaceutical compositions |
| 06/20/2002 | WO2002047680A2 Use of tocopherol, metabolites or derivatives thereof or flavonoid metabolites or derivatives thereof in the manufacture of a medicament for the treatment of tissue ischemia |
| 06/20/2002 | WO2002047673A2 Methods and compositions to treat conditions associated with neovascularization |
| 06/20/2002 | WO2002047660A1 Pharmaceutical dronedarone composition for parenteral administration |
| 06/20/2002 | WO2002047604A2 Novel use of chalcone class compounds for inhibiting tumoral mass vascularization |
| 06/20/2002 | WO2002047456A2 Urotensin-ii receptor antagonists |
| 06/20/2002 | WO2002040019A8 Benzimidazole derivatives |
| 06/20/2002 | WO2002030888A3 Tricyclic compounds and uses thereof |
| 06/20/2002 | WO2002028406A3 Induction of blood vessel formation by polynucleotides encoding sphingosine kinases |
| 06/20/2002 | WO2002024681A3 Pyrazine derivatives as modulators of tyrosine kinases |
| 06/20/2002 | WO2002022571A3 Compounds and methods for inhibiting alpha-1 beta-1 integrins |
| 06/20/2002 | WO2002022074A3 Use of 2- and 4- quinolones for inhibiting intimal neo-proliferation |
| 06/20/2002 | WO2002020495A3 Inhibitors of glycogen synthase kinase 3 |
| 06/20/2002 | WO2002016312A3 NOVEL COMPOUNDS INHIBITING FACTOR Xa ACTIVITY |
| 06/20/2002 | WO2002012214A3 Non-imidazole aryloxyalkylamines as h3 receptor ligands |
| 06/20/2002 | WO2002002092A3 Compositions based on aminoacids, suitable for improving muscle performance |
| 06/20/2002 | WO2001095831A3 Cardiac disease treatment and device |
| 06/20/2002 | WO2001094613A3 Methods and compounds for influencing beta3 integrin-dependent intracellular processes |
| 06/20/2002 | WO2001089570A3 Combination of growth hormone secretagogues and antidepressants |
| 06/20/2002 | WO2001088104A3 Neural progenitor cell populations |
| 06/20/2002 | WO2001085959A3 Regulation of human lysostaphin-like protease |
| 06/20/2002 | WO2001085942A3 Cytoskeleton-associated proteins |
| 06/20/2002 | WO2001080825A3 Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof |
| 06/20/2002 | WO2001078699A3 Use of bradycardiac substances in the treatment of myocardial diseases associated with hypertrophy and novel medicament combinations |
| 06/20/2002 | WO2001077164A3 Diagnosis of diseases associated with apoptosis by means of assessing the methylation status of genes associated with apoptosis |
| 06/20/2002 | WO2001074904A3 G-protein coupled receptors and nucleic acids encoding same |
| 06/20/2002 | WO2001072830A3 Diagnostic and medicament for analysing the cell surface proteome of tumour and inflammatory cells and for treating tumorous and inflammatory diseases, preferably using a specific chemokine receptor analysis and the chemokine receptor-ligand interaction |
| 06/20/2002 | WO2001070231A3 Use of substances modulating the expression or the function of a protein involved in the cell cycle for treating or preventing acute neural injuries |
| 06/20/2002 | WO2001068851A3 Polypeptides and nucleic acids encoding same |
| 06/20/2002 | WO2001062298A3 Compositions and methods for treatment of angiogenesis in pathological lesions |
| 06/20/2002 | WO2001056590A3 Utilization of protein kinase inhibitor alpha |
| 06/20/2002 | WO2001030328A3 Use of 2-amino-3,4-dihydro-quinazolines for producing a medicament for treating or preventing diseases caused by ischaemic conditions |
| 06/20/2002 | WO2001003688A3 Treatment of cyclooxygenase-2 mediated disorders using conjugated fatty acid compounds |
| 06/20/2002 | WO2000067734A3 Use of phthalazine derivatives |
| 06/20/2002 | WO2000061750A9 TYROSINE KINASE SUBSTRATE (Tks) PROTEINS |
| 06/20/2002 | WO2000061596A8 50 human secreted proteins |
| 06/20/2002 | WO2000052159A9 Methods and reagents for inhibiting proliferation of smooth muscle cells |
| 06/20/2002 | WO2000052158A9 Methods and reagents for inhibiting angiogenesis |
| 06/20/2002 | US20020077520 Device and method for dilating and irradiating a vascular segment or body passageway |
| 06/20/2002 | US20020077506 For therapy of inflammatory or painful disorder |
| 06/20/2002 | US20020077486 Platelet ADP receptor inhibitors |
| 06/20/2002 | US20020077468 Corticotropin-releasing factor2 receptors |
| 06/20/2002 | US20020077465 Nuceotide sequences coding enzymatic polypeptide for use in the treatment and prevention of inflammation, cancer, muuscle disorders and thrombosis |
| 06/20/2002 | US20020077361 Can be administered with conventional drugs to treat psychiatric or central nervous disorders to improve their efficacy or reduce their side effects |
| 06/20/2002 | US20020077360 Administering to a mammal a retinoid campound which binds specifically or selectively to a RAR alpha retinoid receptors in preference over RAR beta and RAR Gamma retinoid receptors, for therapy and prophylaxisof disease or condition |
| 06/20/2002 | US20020077356 Nonsteroidal antiinflammatory agents |
| 06/20/2002 | US20020077355 Administering to a subject having a cerebrovascular condition, an epoxyeicosatrienoic acid in an amount effective to reduce brain injury |
| 06/20/2002 | US20020077344 For therapy and prophylaxis of high blood pressure, cardiac hypertrophy, cardiac insufficiency, coronary heart diseases such as angina pectoris, cardiac infarct, vascular restenosis after angioplasty, cardiomyopathies, endothelial dysfunction |
| 06/20/2002 | US20020077342 For use in therapy of epilepsy, depression, tension, gastrointestinal disorders, pain, inflammation |
| 06/20/2002 | US20020077340 Pyridone inhibitors of fatty acid binding protein and method |
| 06/20/2002 | US20020077337 Chemical compounds |
| 06/20/2002 | US20020077333 For therapy inflammation, inflammatory diseases, immunologic diseases and other diseases mediated by tumor necrosis factor-alpha (TNF-alpha) and/or interleukin 6 or 10 and/or enzyme cyclooxygenase-2 (COX-2) |
| 06/20/2002 | US20020077329 EP4 receptor inhibitors to treat rheumatoid arthritis |
| 06/20/2002 | US20020077324 Novel polyhydroxypyrazine derivatives, their preparation and the pharmaceutical compostions which comprise them |
| 06/20/2002 | US20020077321 For therapy of tumor metastasis, solid tumor growth (neoplasia), osteoporosis, Paget's disease, humoral hypercalcemia of malignancy, osteopenia, angiogenesis, including tumor angiogenesis and lymphangiogenesis |
| 06/20/2002 | US20020077319 Combination of GABA agonists and aldose reductase inhibitors |
| 06/20/2002 | US20020077316 For therapy and prophylaxis of cardiovascular disease, dyslipidemia; dyslipoproteinemia; disorder of glucose metabolism; Alzheimer's Disease; Syndrome X; peroxisome proliferator activated receptor-associated disorder |
| 06/20/2002 | US20020077296 High-throughput screening method |
| 06/20/2002 | US20020077283 Blocking interaction of caveolin with a protein in vivo by administering peptide which comprises caveolin scaffolding domain |
| 06/20/2002 | US20020076796 2786, a novel human aminopeptidase |
| 06/20/2002 | US20020076793 Interleukin-1 beta converting enzyme like apoptosis protease-3 and 4 |
| 06/20/2002 | US20020076783 Plants and plants cells expressing histidine tagged intimin |
| 06/20/2002 | US20020076766 Novel glucosaminidase |
| 06/20/2002 | US20020076705 Nucleotide sequences which code preferential polypeptide; for use in the detection, treatment, and prevention of alzheimer's, parkinson's, huntington's, Tourette Syndrome, meningitis, encephalitis, congenital disorders and brain |